Judith Ng-Cashin
Nessuna posizione attualmente
Profilo
Judith Ng-Cashin served as the Chief Medical Officer at AOBiome Therapeutics, Inc. She also served as the Chief Medical Officer and Executive Vice President at Eagle Pharmaceuticals, Inc. Prior to her professional roles, she earned an undergraduate degree from Duke University and a doctorate from Rush Medical College.
Precedenti posizioni note di Judith Ng-Cashin
Società | Posizione | Fine |
---|---|---|
EAGLE PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 27/12/2021 |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Judith Ng-Cashin
Duke University | Undergraduate Degree |
Rush Medical College | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
EAGLE PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 1 |
---|---|
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Judith Ng-Cashin